[ad_1]
She is proud of her work, her team and the level of science carried out in Tucuman, Florencia González Lizárraga He is grateful for the difference he received from the Argentine Association for Biophysics, the institution which is the most important species in the country. He received the Jorge Ponce Hornos Award after being selected among 350 works by scientists from all over the country. "This work represents my doctoral dissertation (she will be a doctor in biological sciences). I am the first author of the work, but we discuss these issues as a team," he explains.
The Florence investigation was carried out at the Institute of Molecular and Cellular Medicine (Immca), which is dependent on UNT, Conicet and the Ministry of Health of the Province, and is responsible for Rosana Chehín. The work also took into account the cooperation of the Center of advanced UBA microscopes, which directs it Lia Pietrasanta. Yesterday it was Florence when speaking on the phone with LA GACETA.
The basis of the research of a young scientist is an antibiotic called dioxycycline, which belongs to the tetracycline group. This antibiotic has the ability to interact with the protein alpha-synuclein responsible for the death of neurosin dopasinergic (those that communicate with other neurons via dopamine). These are neurons that die in those who suffer from Parkinson's disease.
But doxycycline is not suitable for long-term diseases, such as neurodegenerative diseases, because it can cause resistance to bacteria.
"The second part is that it found COL 3, which is also tetracycline, but genetically modified, so it does not have antibiotic activity, so it will not cause resistance, and has anti-inflammatory action and makes the protein alpha-syncline non-toxic. Consequently, no death dopano-neurons.
"In this way, Parkinson's disease stops, which means that there is no palliative treatment, such as the current treatment," Florencia points out.
Of course, the research is still in the laboratory phase. In vitro and in vivo tests are performed, but it is still far from the level of clinical trials in humans. Nevertheless, there is undoubtedly a great hope.
Another mention of the Ponce Hornos Prize was Tucuman: Luciana Medina, to work on Alzheimer's disease.
[ad_2]
Source link